Cellectis is developing the first of its kind allogeneic approach for CAR-T immunotherapies in oncology, pioneering the concept of off-the-shelf and ready-to-use gene-edited CAR T-cells to treat cancer patients. As a clinical-stage biopharmaceutical company with over 24 years of expertise in gene editing, Cellectis is developing life-changing product candidates utilizing TALEN®, its proprietary gene editing technology, and PulseAgile, its pioneering electroporation system to harness the power of the immune system in order to target and eradicate cancer cells. As part of its commitment to a cure, Cellectis remains dedicated to its goal of providing life-saving UCART product candidates to address unmet needs for multiple cancers including B-cell acute lymphoblastic leukemia (B-ALL), non-Hodgkin lymphoma (NHL) and acute myeloid leukemia (AML). Cellectis headquarters are in Paris, France, with additional locations in New York, New York and Raleigh, North Carolina. Cellectis is listed on the Nasdaq Global Market (ticker: CLLS) and on Euronext Growth (ticker: ALCLS). To find out more about us, visit our website: www.cellectis.com. To learn more about our community guidelines, visit: http://www.cellectis.com/en/social-media-guidelines/ Follow our other social media accounts: @cellectis on Twitter and Cellectis YouTube TALEN® is a registered trademark owned by the Cellectis Group.
View Top Employees from CellectisWebsite | https://www.cellectis.com/ |
Ticker | CLLS |
Revenue | $41.4 million |
Funding | $478.9 million |
Employees | 261 (261 on RocketReach) |
Founded | 1999 |
Address | 8 Rue De La Croix Jarry, Paris, Ile-de-France 75013, FR |
Phone | +33 1 81 69 16 00 |
Fax | +33 1 81 69 16 06 |
Technologies |
JavaScript,
HTML,
PHP
+17 more
(view full list)
|
Industry | Biotechnology Research, Pharmaceuticals, Biopharma, Gene editing, Healthcare, Biotechnology, Life sciences, Health Care, Oncology, Science and Engineering, T-Cell therapies, Medical, Genome Engineering |
Web Rank | 928761 |
Keywords | Gene Editing, Cancer Treatment, Cell Therapies |
SIC | SIC Code 873 Companies, SIC Code 87 Companies |
NAICS | NAICS Code 3254 Companies, NAICS Code 32541 Companies, NAICS Code 32 Companies, NAICS Code 62 Companies, NAICS Code 325 Companies, NAICS Code 621 Companies |
Looking for a particular Cellectis employee's phone or email?
The Cellectis annual revenue was $41.4 million in 2024.
261 people are employed at Cellectis.
Cellectis is based in Paris, Ile-de-France.
The NAICS codes for Cellectis are [3254, 32541, 32, 62, 325, 621].
The SIC codes for Cellectis are [873, 87].